Filing Flows

Filing Flows › Companies › Mimedx Group › Cash flow

Mimedx Group cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$3.9M in Q3 2026 · $20.7M over twelve months

Operating cash flow$3.9M
Free cash flow+$3.9M
Cash conversion cycle142 days

Analysis

In Q3 2026, Mimedx Group generated $3.9M of operating cash flow. That is $25.4M less than in Q3 2025 ($29.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was $20.7M; the largest uses were other financing ($20.3M), buybacks ($12.8M), acquisitions ($5.0M); the cash balance fell by $21.3M.

Operating cash flow was $3.9M against net income of −$8.7M. The largest differences: payables +$3.5M, stock-based pay +$3.2M, employee-related liabilities +$2.7M.

Its cash conversion cycle was 142 days (receivables 58 + inventory 157 − payables 74).

Free cash flow

Mimedx Group: free cash flow by quarterMimedx Group: free cash flow by quarter$18.8MQ4 2024$5.3MQ1 2025$14.4MQ2 2025$29.3MQ3 2025$25.0MQ4 2025$1.9MQ1 2026−$10.0MQ2 2026$3.9MQ3 2026
Operating cash flow less capital spending.
Mimedx Group: operating cash flow against capital spendingMimedx Group: operating cash flow against capital spendingOperating cash flowCapital spending$18.8M$0Q4 2024$5.3M$0Q1 2025$14.4M$0Q2 2025$29.3M$0Q3 2025$25.0M$0Q4 2025$1.9M$0Q1 2026−$10.0M$0Q2 2026$3.9M$0Q3 2026
Latest (Q3 2026): Operating cash flow $3.9M, Capital spending $0.

Capital allocation, year by year

Mimedx Group: where the cash came from (up) and went (down), by fiscal yearMimedx Group: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$2.0MFY2021: Net borrowing −$38KFY2021: Shares issued $1.4MFY2021: Capital spending −$3.2M$1.4MFY2021FY2022: Operating cash flow −$17.9MFY2022: Net borrowing −$41KFY2022: Shares issued $651KFY2022: Asset sales $24KFY2022: Capital spending −$1.5M$675KFY2022FY2023: Operating cash flow $26.8MFY2023: Net borrowing −$52KFY2023: Shares issued $997KFY2023: Capital spending −$2.0MFY2023: Buybacks −$9.5M$27.8MFY2023FY2024: Operating cash flow $66.2MFY2024: Net borrowing −$30.2MFY2024: Shares issued $1.4MFY2024: Acquisitions −$7.9M$67.6MFY2024FY2025: Operating cash flow $74.0MFY2025: Acquisitions −$3.8M$74.0MFY2025
Over these 5 years operating cash flow totalled $147M; the largest uses were net borrowing ($30.3M) and operating cash flow ($19.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$121M
Debt$18.0M
Net cash$103M
Due within a year$1.5M

Mimedx Group funds itself: free cash flow was $20.7M over the last twelve months, and $121M of cash and investments stands against $18.0M of debt ($1.5M due within a year, 80.5× covered by cash).

Mimedx Group: debt maturities by year (FY2025)Mimedx Group: debt maturities by year (FY2025)$1.5MYear 1$1.5MYear 2$2.0MYear 3$13.0MYear 4
Principal due in each year as disclosed in the annual report, against $121M of cash and investments now.

Where the cash came from and went

Mimedx Group: sources (+) and uses (−) of cash, Q3 2026Mimedx Group: sources (+) and uses (−) of cash, Q3 2026Other financing−$18.4MCash drawn (+) / kept (−)$15.0MOperating cash flow$3.9MBuybacks−$304KOther investing−$193KTaxes on employees’ shares−$68K
Mimedx Group: sources (+) and uses (−) of cash, TTM to Q3 2026Mimedx Group: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)$21.3MOperating cash flow$20.7MOther financing−$20.3MBuybacks−$12.8MAcquisitions−$5.0MTaxes on employees’ shares−$2.1MOther investing−$1.8M

From profit to cash

Mimedx Group: net income to operating cash flow, Q3 2026Mimedx Group: net income to operating cash flow, Q3 2026Net income−$8.7MDepreciation & amortization$665KStock-based pay$3.2MReceivables$1.8MInventory−$1.2MPayables$3.5MAccrued liabilities$1.5MEmployee-related liabilities$2.7MPrepaid and other assets$453KOther liabilities−$158KOperating cash flow$3.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265815774142
Q2 20266210745124
Q1 20269313467159
Q4 20256012563122
Q3 20256012649137
Q2 20256111942138
Q1 20256013044146
Q4 20245413139146

Every quarter

QuarterOperating cash flowAcquisitionsBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$3.9M—−$304K—$15.0M$3.9M
Q2 2026−$10.0M———$23.9M−$10.0M
Q1 2026$1.9M−$5.0M——$6.3M$1.9M
Q4 2025$25.0M———−$24.0M$25.0M
Q3 2025$29.3M−$3.1M——−$23.2M$29.3M
Q2 2025$14.4M−$700K——−$12.4M$14.4M
Q1 2025$5.3M———−$2.0M$5.3M
Q4 2024$18.8M−$2.5M—−$1K−$15.6M$18.8M

Mimedx Group: income statement and cash flow

Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%. The chart follows the revenue to costs, profit and cash.

Mimedx Group: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.